查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1717184

細胞和基因治療市場（按治療類型、交付方式、治療領域、應用和最終用戶分類）—2025-2030 年全球預測

Cell & Gene Therapy Market by Therapy Type, Delivery Method, Therapeutic Areas, Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年細胞和基因治療市場價值將達到143.3億美元，2024年將達到166.5億美元，複合年成長率為18.98%，到2030年將達到483.9億美元。

主要市場統計數據
基準年2023年 143.3億美元
預計2024年 166.5億美元
預測年份 2030 483.9億美元
複合年成長率（%） 18.98%

細胞和基因治療產業處於現代醫學的前沿，代表著治療慢性、危及生命的疾病方法的模式轉移。近年來，創新突破和監管進步推動該領域進入了治療前景的新時代。由於科學發現的快速發展、生物技術投資的增加以及對分子水平上疾病病理生理學理解的提高，該市場正在經歷強勁成長。這些治療方法不僅提供了持久緩解甚至治癒的可能性，而且為數百萬以前治療選擇有限或沒有治療選擇的患者帶來了希望。該部門專注於個人化醫療，不斷彌合研究與臨床應用之間的差距，並建立促進臨床和學術合作的綜合平台。從研究人員和臨床醫生到投資者和政策制定者，所有相關人員都認知到細胞和基因治療的巨大潛力，並將其轉變為科學嚴謹性和商業性機會的沃土。

隨著市場日趨成熟，技術創新擴大融入以患者為中心的成果。先進的基因組技術、複雜的細胞工程技術和改進的給藥方法的融合為不僅更有效且越來越容易獲得的治療方法鋪平了道路。這一轉變標誌著藥物研發的策略轉折，並正在影響產業領導者的投資策略和業務運作。對治療方案的需求，加上我們正站在治療發展新時代的風口浪尖上專家們重新燃起的樂觀情緒，正在推動該行業快速發展。

改變細胞和基因治療市場

近年來，細胞和基因治療產業經歷了一系列變革，重新定義了市場動態和主要參與者的商業策略。一個關鍵的變化是尖端生物技術平台的開發和整合，這使得治療更加精確和有效。隨著科學進步不斷揭示細胞功能和基因表現的複雜性，突破性的治療方法已迅速從概念驗證轉向臨床應用。監管機構也更新了核准途徑，縮短了開發時間，為更靈活的市場進入鋪平了道路。這些監管改革，加上公共和私人資金的增加，正在刺激更大的創新並加快治療方法進入市場的速度。

同時，數位分析工具和即時數據收集的採用正在改變臨床試驗的格局，從而帶來更穩健和更具適應性的試驗設計。如今，數據分析與對分子生物學的深刻理解相結合，推動著創新，治療方法不僅針對典型的患者特徵，還針對不同的遺傳背景和疾病亞型。整合先進製造技術和可擴展調查方法的能力在緩解生產挑戰和成本限制方面也發揮關鍵作用。這些趨勢表明，細胞和基因療法的方面和商業性方面都在迅速發展，凸顯了持續適應、合作和增加對顛覆傳統治療方法主導格局的新技術的投資的必要性。

細胞和基因治療市場的關鍵細分洞察

了解市場區隔可以為了解細胞和基因治療領域的多面結構提供寶貴的見解。市場主要根據治療方法類型進行細分，其中兩個主要領域是細胞治療和基因治療。在細胞治療領域，甚至對幹細胞治療和T細胞治療等細分領域也正在進行詳細的分析。在幹細胞治療中，造血幹細胞治療和間質幹細胞治療有區別，而在T細胞治療中，正在研究CAR-T細胞治療和使用T細胞受體的方法。相反，基因治療可分為體外基因治療和體內基因治療，它們代表改變基因功能或表現的不同方法。

從另一個角度來看，市場區隔也受到這些治療所採用的給藥方式的影響，主要著重於肌肉注射和靜脈注射。此外，治療應用涉及心血管、代謝和神經病變疾病、腫瘤學和眼科學等幾個主要領域。每個治療領域都需要更深入的研究。例如，心血管應用進一步分為鬱血性心臟衰竭衰竭和缺血性心臟疾病等病症，而代謝紊亂則集中於糖尿病和肥胖症。同樣，神經系統疾病包括阿茲海默症、亨丁頓舞蹈症、多發性硬化症、巴金森氏症和脊髓損傷，而腫瘤學則著重於血液系統惡性腫瘤、淋巴瘤和固態腫瘤。

此外，這些治療方法的用途分為臨床用途和研發用途，其中臨床用途類別進一步分為疾病預防和治療。最後，我們的最終用戶細分區分了學術和研究機構，包括私人實驗室和大學，以及直接為患者提供護理的醫院和診所。這些細分洞察構成了策略決策的基礎，並使相關人員能夠準確地識別市場利基和成長機會。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 全球遺傳疾病和罕見疾病的發生率正在上升
      • 個人化醫療意識和需求不斷成長
    • 限制因素
      • 與細胞和基因治療相關的複雜製造流程和品管問題
    • 機會
      • 現成的細胞治療方法的開發為大量患者提供了可擴展的解決方案。
      • 擴大生物技術與製藥公司之間的合作，加強研發
    • 任務
      • 政府對新基因療法的嚴格監管和核准程序
  • 市場區隔分析
    • 治療類型：優先考慮T細胞療​​法，標靶並摧毀癌細胞
    • 給藥方法：利用肌肉注射系統減少侵襲性
    • 治療領域：心血管護理中對細胞和基因療法的需求不斷成長，以尋求長期解決方案
    • 應用：在臨床應用中使用細胞和基因療法透過改變基因組成來直接治療和預防疾病。
    • 最終用戶：在醫院和診所採用細胞和基因療法來改善治療效果和患者滿意度
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社會
    • 技術的
    • 合法的
    • 環境

第6章細胞與基因治療市場（依治療類型）

  • 細胞療法
    • 幹細胞療法
      • 造血幹細胞治療
      • 間質幹細胞治療
    • T細胞療法
      • CAR-T細胞療法
      • 基於 T 細胞受體 (TCR)
  • 基因治療
    • 體外基因治療
    • 體內基因治療

第7章 細胞和基因治療市場（以交付方式）

  • 肌肉注射
  • 靜脈

第8章細胞和基因治療市場（按治療領域）

  • 心血管系統
    • 鬱血性心臟衰竭衰竭
    • 缺血性心臟疾病
  • 代謝紊亂
    • 糖尿病
    • 肥胖
  • 神經系統疾病
    • 阿茲海默症
    • 亨丁頓舞蹈症
    • 多發性硬化症
    • 帕金森氏症
    • 脊髓損傷
  • 腫瘤學
    • 造血系統惡性腫瘤
    • 淋巴瘤
    • 固態腫瘤
  • 眼科

第9章細胞和基因治療市場（按應用）

  • 臨床應用
    • 疾病預防
    • 疾病治療
  • 研究與開發

第 10 章 細胞和基因治療市場（按最終用戶）

  • 學術研究所
    • 私人研究實驗室
    • 大學
  • 醫院和診所

第 11 章：美洲細胞與基因治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

12. 亞太細胞與基因治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

13. 歐洲、中東和非洲細胞和基因治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023年市場佔有率分析
  • 2023年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • AbbVie Inc.
  • Abeona Therapeutics Inc.
  • Adaptimmune Therapeutics PLC
  • AGC Inc.
  • Alnylam Pharmaceuticals, Inc.
  • American Gene Technologies Inc.
  • Amgen Inc.
  • AnGes, Inc
  • Astellas Pharma Inc.
  • Becton, Dickinson and Company
  • Biogen Inc.
  • Bluebird Bio, Inc.
  • BridgeBio Pharma, Inc.
  • Bristol-Myers Squibb Company
  • CH Boehringer Sohn AG & Co. KG
  • Cellectis SA
  • CRISPR Therapeutics AG
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • Intellia Therapeutics, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Johnson & Johnson Services Inc.
  • Kyowa Kirin Co., Ltd.
  • Merck KGaA
  • Moderna, Inc.
  • Mustang Bio, Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer, Inc.
  • REGENXBIO Inc.
  • Sangamo Therapeutics, Inc.
  • Sarepta Therapeutics, Inc.
  • Shoreline Biosciences
  • Sibiono GeneTech Co. Ltd.
  • Syncona Limited
  • Thermo Fisher Scientific Inc.
  • Vertex Pharmaceuticals Incorporated
Product Code: MRR-450A0628CE5A

The Cell & Gene Therapy Market was valued at USD 14.33 billion in 2023 and is projected to grow to USD 16.65 billion in 2024, with a CAGR of 18.98%, reaching USD 48.39 billion by 2030.

KEY MARKET STATISTICS
Base Year [2023] USD 14.33 billion
Estimated Year [2024] USD 16.65 billion
Forecast Year [2030] USD 48.39 billion
CAGR (%) 18.98%

The cell and gene therapy industry stands at the forefront of modern medicine, representing a paradigm shift in our approach to treating life-threatening and chronic diseases. Over recent years, innovative breakthroughs and regulatory advancements have propelled this field into a new era of therapeutic promise. The market has experienced robust growth due to rapid scientific discoveries, increased investments in biotechnology, and an enhanced understanding of disease pathophysiology at the molecular level. These therapies not only offer the possibility of durable remissions and cures but also provide hope to millions of patients who previously had limited or no treatment options. With a strong emphasis on personalized medicine, the sector continues to bridge the gap between research and clinical application, establishing integrated platforms that foster both clinical and academic collaborations. Stakeholders across the board-from researchers and clinicians to investors and policy makers-have recognized the immense potential embedded within the cell and gene therapy landscape, transforming it into a fertile ground for scientific rigor and commercial opportunity.

As the market maturing further, innovation becomes increasingly interwoven with patient-centric outcomes. The convergence of advanced genomic technologies, refined cell manipulation techniques, and improved delivery methodologies has paved the way for therapies that are not only highly effective but also increasingly accessible. This transformation signals a strategic pivot in drug development, influencing the investment strategies and operational frameworks of industry leaders. The industry is evolving rapidly, driven by a combination of demand for curative treatment options and a renewed optimism among professionals that stand at the threshold of a new era in therapeutic development.

Transformative Shifts in the Cell & Gene Therapy Landscape

Recent years have witnessed a multitude of transformative shifts within the cell and gene therapy industry that have redefined both the market dynamics and the operational strategies of key players. One pivotal change has been the development and integration of state-of-the-art biotechnological platforms, which have enabled more precise and effective therapies. As scientific advances continue to unravel the complexities of cellular functions and genetic expressions, breakthrough treatments have moved quickly from proof-of-concept to clinical application. Regulatory agencies have also updated approval pathways, shortening the developmental timeline and making way for more agile market entries. These regulatory reforms are coupled with increased public and private funding, which has further catalyzed innovation and accelerated the pace at which therapies are being brought to market.

In parallel, the adoption of digital analytical tools and real-time data collection has revolutionized the clinical trial landscape, leading to more robust and adaptive study designs. Innovation is now driven by a combination of data analytics and an in-depth understanding of molecular biology, resulting in therapies that cater not only to the typical patient profile but also to diverse genetic backgrounds and disease subtypes. The ability to integrate advanced manufacturing techniques with scalable research methodologies has also played a crucial role in mitigating production challenges and cost constraints. These trends indicate that both the scientific and commercial aspects of cell and gene therapy are undergoing rapid evolution, underscoring the need for continuous adaptation, collaborative research, and increased investment in novel technologies that are transforming the landscape once dominated by traditional therapeutic approaches.

Key Segmentation Insights in the Cell & Gene Therapy Market

Understanding the market segmentation provides valuable insights into the multifaceted structure of the cell and gene therapy domain. The market is primarily categorized based on therapy type, where the two main domains are cell therapy and gene therapy. In the realm of cell therapy, detailed analyses extend to subdivisions such as stem cell therapies and T cell therapy. Within stem cell therapies, a distinction is made between hematopoietic stem cell therapies and mesenchymal stem cell therapies, while T cell therapy is examined through the lenses of CAR T cell therapy and T cell receptor-based approaches. Conversely, gene therapy is dissected into ex vivo gene therapy and in vivo gene therapy, representing distinct approaches to modifying genetic function and expression.

From another perspective, market segmentation is also driven by the delivery method utilized in these therapies, predominantly focusing on intramuscular and intravenous techniques. In addition, the therapeutic application spectrum spans several key areas, including cardiovascular issues, metabolic disorders, neurological disorders, oncology, and ophthalmology. Each therapeutic area is subject to deeper investigation; for example, cardiovascular applications are further divided into conditions such as congestive heart failure and ischemic heart disease, whereas metabolic disorders focus on diabetes and obesity. Similarly, neurological disorders encompass a range of conditions spanning Alzheimer's disease, Huntington's disease, multiple sclerosis, Parkinson's disease, and spinal cord injuries, and oncology is studied with respect to hematological malignancies, lymphomas, and solid tumors.

Furthermore, the application of these therapies is split into those used for clinical applications and those intended for research and development, with the clinical category further delineated into disease prevention and treatment. Lastly, the end-user segmentation distinguishes between academic and research institutes, which include private research labs and universities, and hospitals and clinics that deliver direct patient care. These segmentation insights serve as the bedrock for strategic decision-making and enable stakeholders to hone in on precise market niches and growth opportunities.

Based on Therapy Type, market is studied across Cell Therapy and Gene Therapy. The Cell Therapy is further studied across Stem Cell Therapies and T Cell Therapy. The Stem Cell Therapies is further studied across Hematopoietic Stem Cell Therapies and Mesenchymal Stem Cell Therapies. The T Cell Therapy is further studied across CAR T Cell Therapy and T Cell Receptor (TCR)-based. The Gene Therapy is further studied across Ex Vivo Gene Therapy and In Vivo Gene Therapy.

Based on Delivery Method, market is studied across Intramuscular and Intravenous.

Based on Therapeutic Areas, market is studied across Cardiovascular, Metabolic Disorders, Neurological Disorders, Oncology, and Ophthalmology. The Cardiovascular is further studied across Congestive Heart Failure and Ischemic Heart Disease. The Metabolic Disorders is further studied across Diabetes and Obesity. The Neurological Disorders is further studied across Alzheimer's Disease, Huntington's Disease, Multiple Sclerosis, Parkinson's Disease, and Spinal Cord Injuries. The Oncology is further studied across Hematological Malignancies, Lymphomas, and Solid Tumors.

Based on Application, market is studied across Clinical Applications and Research & Development. The Clinical Applications is further studied across Disease Prevention and Disease Treatment.

Based on End User, market is studied across Academic & Research Institutes and Hospitals & Clinics. The Academic & Research Institutes is further studied across Private Research Labs and Universities.

Key Regional Insights Shaping the Global Market

Global trends in the cell and gene therapy market are not uniform, but vary substantially across key regions. The Americas continues to lead with a broad network of research and high levels of investment, bolstering national initiatives in biotechnology innovation and product commercialization. This region benefits from a well-developed reimbursement and regulatory environment that supports the rapid introduction of innovative therapies.

In regions grouped under Europe, Middle East & Africa, there is a significant focus on balancing innovation with strict regulatory oversight. These regions have been proactive in adopting global standards in clinical research while fostering local advancements through strategic public-private partnerships. Recent policy changes and increased research funding have enabled these markets to narrow the gap between traditional treatments and novel curative approaches. Finally, the Asia-Pacific region is emerging as a critical hub for both research and manufacturing. Rapid economic growth, coupled with large-scale governmental investments in science and technology, have positioned this region as an attractive destination for clinical trials and cost-efficient manufacturing of advanced therapies. In summary, while each region exhibits unique characteristics, there is a clear convergence in striving towards accelerated innovation and improved patient outcomes on a global scale.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Shaping the Cell & Gene Therapy Ecosystem

The competitive landscape in the cell and gene therapy market is marked by a diverse set of companies that are not only investing in innovative research but are also committed to scaling manufacturing processes and clinical execution. Industry pioneers such as AbbVie Inc., Amgen Inc., and Bristol-Myers Squibb Company have been instrumental in driving forward high-impact clinical programs. Other notable companies like Abeona Therapeutics Inc., Adaptimmune Therapeutics PLC, and AGC Inc. continue to push the envelope with novel therapeutic modalities.

This realm also includes outstanding contributions from companies like Alnylam Pharmaceuticals, Inc., American Gene Technologies Inc., and AnGes, Inc., each bringing unique expertise to the forefront of cell and gene therapies. The competitive field is further enriched by industry leaders such as Astellas Pharma Inc., Becton, Dickinson and Company, and Biogen Inc., who have consistently showcased innovations that translate laboratory research into effective clinical results. Bluebird Bio, Inc.? BridgeBio Pharma, Inc.? and C.H. Boehringer Sohn AG & Co. KG are also at the cutting edge, alongside emerging firms like Cellectis SA, CRISPR Therapeutics AG, and F. Hoffmann-La Roche AG. The dynamic interplay between these companies, including Gilead Sciences, Inc., Intellia Therapeutics, Inc., Ionis Pharmaceuticals, Inc., and Johnson & Johnson Services Inc., emphasizes the symbiotic relationship between rapid technological evolution and comprehensive market strategies. Further, key players such as Kyowa Kirin Co., Ltd., Merck KGaA, Moderna, Inc., Mustang Bio, Inc., Novartis AG, Novo Nordisk A/S, Pfizer, Inc., REGENXBIO Inc., Sangamo Therapeutics, Inc., Sarepta Therapeutics, Inc., Shoreline Biosciences, Sibiono GeneTech Co. Ltd., Syncona Limited, Thermo Fisher Scientific Inc., and Vertex Pharmaceuticals Incorporated help to illustrate the competitive dynamism and technical depth of the market, driving forward advancements that promise to reshape therapeutic landscapes worldwide.

The report delves into recent significant developments in the Cell & Gene Therapy Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Abeona Therapeutics Inc., Adaptimmune Therapeutics PLC, AGC Inc., Alnylam Pharmaceuticals, Inc., American Gene Technologies Inc., Amgen Inc., AnGes, Inc, Astellas Pharma Inc., Becton, Dickinson and Company, Biogen Inc., Bluebird Bio, Inc., BridgeBio Pharma, Inc., Bristol-Myers Squibb Company, C.H. Boehringer Sohn AG & Co. KG, Cellectis SA, CRISPR Therapeutics AG, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., Intellia Therapeutics, Inc., Ionis Pharmaceuticals, Inc., Johnson & Johnson Services Inc., Kyowa Kirin Co., Ltd., Merck KGaA, Moderna, Inc., Mustang Bio, Inc., Novartis AG, Novo Nordisk A/S, Pfizer, Inc., REGENXBIO Inc., Sangamo Therapeutics, Inc., Sarepta Therapeutics, Inc., Shoreline Biosciences, Sibiono GeneTech Co. Ltd., Syncona Limited, Thermo Fisher Scientific Inc., and Vertex Pharmaceuticals Incorporated. Actionable Recommendations for Industry Leaders

Industry leaders are encouraged to embrace innovation by integrating advanced data analytics and digital health platforms to streamline research and development. Given the high complexity of therapeutic modalities, investing in scalable manufacturing and maintaining strong regulatory communications are essential. Leaders should focus on building strategic partnerships that leverage cross-functional expertise and promote shared risk in clinical advancements. An agile approach to commercialization and the incorporation of real-world evidence can greatly enhance market acceptance and patient outcomes. Fostering robust collaborations across academic, clinical, and industrial spectrums will pave the way to a sustainable and competitive future in the evolving therapeutic landscape.

Conclusion: Summarizing the Evolution and Future Prospects

The cell and gene therapy market is undergoing a transformative evolution propelled by significant scientific, regulatory, and technological advancements. A thorough analysis reveals that evolving segmentation strategies, insightful regional trends, and a competitive roster of innovative companies collectively underscore the growth potential of this field. The industry is well positioned to continue transforming the treatment landscape, delivering unprecedented outcomes for patients across diverse therapeutic areas. This report culminates in a clear message; that sustained innovation, strategic investment, and collaborative industry partnerships are essential to navigate the complexities and realize the promise of breakthrough therapies. The insights derived from market analysis not only elucidate current trends but also serve as a roadmap for sustained growth and commercial success in an ever-evolving industry.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of genetic disorder and rare disease globally
      • 5.1.1.2. Growing awareness and rising demand for personalised medicine
    • 5.1.2. Restraints
      • 5.1.2.1. Complex production processes and quality control issues associated with cell & gene therapy
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of off-the-shelf cell therapies offers scalable solutions for large patient populations
      • 5.1.3.2. Rising collaboration between biotechnology and pharmaceutical companies for enhanced research & development
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent governmental regulation & approval procedures for new gene therapies
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Therapy Type: Preference for T cell therapy to target and destroy cancer cells
    • 5.2.2. Delivery Method: Utilization of intramuscular delivery system to reduced invasiveness
    • 5.2.3. Therapeutic Areas: Rising demand of cell & gene therapy in cardiovascular therapeutics for long lasting solutions
    • 5.2.4. Application: Usage of cell & gene therapy in clinical applications to directly treat and prevent diseases by altering genetic makeup
    • 5.2.5. End User: Adoption of cell & gene therapy in hospital & clinics to enhance treatment outcomes and patient satisfaction
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cell & Gene Therapy Market, by Therapy Type

  • 6.1. Introduction
  • 6.2. Cell Therapy
    • 6.2.1. Stem Cell Therapies
      • 6.2.1.1. Hematopoietic Stem Cell Therapies
      • 6.2.1.2. Mesenchymal Stem Cell Therapies
    • 6.2.2. T Cell Therapy
      • 6.2.2.1. CAR T Cell Therapy
      • 6.2.2.2. T Cell Receptor (TCR)-based
  • 6.3. Gene Therapy
    • 6.3.1. Ex Vivo Gene Therapy
    • 6.3.2. In Vivo Gene Therapy

7. Cell & Gene Therapy Market, by Delivery Method

  • 7.1. Introduction
  • 7.2. Intramuscular
  • 7.3. Intravenous

8. Cell & Gene Therapy Market, by Therapeutic Areas

  • 8.1. Introduction
  • 8.2. Cardiovascular
    • 8.2.1. Congestive Heart Failure
    • 8.2.2. Ischemic Heart Disease
  • 8.3. Metabolic Disorders
    • 8.3.1. Diabetes
    • 8.3.2. Obesity
  • 8.4. Neurological Disorders
    • 8.4.1. Alzheimer's Disease
    • 8.4.2. Huntington's Disease
    • 8.4.3. Multiple Sclerosis
    • 8.4.4. Parkinson's Disease
    • 8.4.5. Spinal Cord Injuries
  • 8.5. Oncology
    • 8.5.1. Hematological Malignancies
    • 8.5.2. Lymphomas
    • 8.5.3. Solid Tumors
  • 8.6. Ophthalmology

9. Cell & Gene Therapy Market, by Application

  • 9.1. Introduction
  • 9.2. Clinical Applications
    • 9.2.1. Disease Prevention
    • 9.2.2. Disease Treatment
  • 9.3. Research & Development

10. Cell & Gene Therapy Market, by End User

  • 10.1. Introduction
  • 10.2. Academic & Research Institutes
    • 10.2.1. Private Research Labs
    • 10.2.2. Universities
  • 10.3. Hospitals & Clinics

11. Americas Cell & Gene Therapy Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Cell & Gene Therapy Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Cell & Gene Therapy Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Novartis acquires Kate Therapeutics to advance gene therapies for neuromuscular diseases
    • 14.3.2. Cellular Origins and Fresenius Kabi sign agreement for automated cell and gene therapy manufacturing
    • 14.3.3. Astellas and AviadoBio exclusive license agreement for AVB-101 gene therapy targeting frontotemporal dementia
    • 14.3.4. Virica Biotech and Ginkgo Bioworks partner to enhance AAV gene therapy production
    • 14.3.5. McKesson launches InspiroGene to enhance cell and gene therapy commercialization
    • 14.3.6. ArsenalBio secures USD 325m for advanced CRISPR T cell therapies targeting solid tumors
    • 14.3.7. Genezen acquires uniQure's Lexington facility to enhance gene therapy manufacturing capabilities
    • 14.3.8. Charles River expands gene therapy collaboration with NUS Medicine to enhance engineered stem cell cancer treatments
    • 14.3.9. AstraZeneca completes acquisition of Gracell Biotechnologies to enhance cell therapy portfolio
    • 14.3.10. AbbVie and Umoja Biopharma collaborate to innovate in-situ CAR-T cell therapies
  • 14.4. Strategy Analysis & Recommendation
    • 14.4.1. Amgen Inc.
    • 14.4.2. F. Hoffmann-La Roche AG
    • 14.4.3. Astellas Pharma Inc.
    • 14.4.4. Bristol-Myers Squibb Company

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Abeona Therapeutics Inc.
  • 3. Adaptimmune Therapeutics PLC
  • 4. AGC Inc.
  • 5. Alnylam Pharmaceuticals, Inc.
  • 6. American Gene Technologies Inc.
  • 7. Amgen Inc.
  • 8. AnGes, Inc
  • 9. Astellas Pharma Inc.
  • 10. Becton, Dickinson and Company
  • 11. Biogen Inc.
  • 12. Bluebird Bio, Inc.
  • 13. BridgeBio Pharma, Inc.
  • 14. Bristol-Myers Squibb Company
  • 15. C.H. Boehringer Sohn AG & Co. KG
  • 16. Cellectis SA
  • 17. CRISPR Therapeutics AG
  • 18. F. Hoffmann-La Roche AG
  • 19. Gilead Sciences, Inc.
  • 20. Intellia Therapeutics, Inc.
  • 21. Ionis Pharmaceuticals, Inc.
  • 22. Johnson & Johnson Services Inc.
  • 23. Kyowa Kirin Co., Ltd.
  • 24. Merck KGaA
  • 25. Moderna, Inc.
  • 26. Mustang Bio, Inc.
  • 27. Novartis AG
  • 28. Novo Nordisk A/S
  • 29. Pfizer, Inc.
  • 30. REGENXBIO Inc.
  • 31. Sangamo Therapeutics, Inc.
  • 32. Sarepta Therapeutics, Inc.
  • 33. Shoreline Biosciences
  • 34. Sibiono GeneTech Co. Ltd.
  • 35. Syncona Limited
  • 36. Thermo Fisher Scientific Inc.
  • 37. Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

  • FIGURE 1. CELL & GENE THERAPY MARKET MULTI-CURRENCY
  • FIGURE 2. CELL & GENE THERAPY MARKET MULTI-LANGUAGE
  • FIGURE 3. CELL & GENE THERAPY MARKET RESEARCH PROCESS
  • FIGURE 4. CELL & GENE THERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 5. GLOBAL CELL & GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES CELL & GENE THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 21. UNITED STATES CELL & GENE THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. CELL & GENE THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 27. CELL & GENE THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CELL & GENE THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CELL & GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CELL & GENE THERAPY MARKET DYNAMICS
  • TABLE 7. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CAR T CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY T CELL RECEPTOR (TCR)-BASED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY EX VIVO GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY IN VIVO GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CONGESTIVE HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ISCHEMIC HEART DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY OBESITY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HUNTINGTON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY SPINAL CORD INJURIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY LYMPHOMAS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DISEASE PREVENTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DISEASE TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY PRIVATE RESEARCH LABS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 56. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY UNIVERSITIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 57. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 58. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 65. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 66. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
  • TABLE 67. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 68. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 69. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 70. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 72. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 73. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 74. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 75. ARGENTINA CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. ARGENTINA CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 77. ARGENTINA CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 78. ARGENTINA CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 79. ARGENTINA CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 80. ARGENTINA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 81. ARGENTINA CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 82. ARGENTINA CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
  • TABLE 83. ARGENTINA CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 84. ARGENTINA CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 85. ARGENTINA CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 86. ARGENTINA CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. ARGENTINA CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 88. ARGENTINA CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 89. ARGENTINA CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 90. BRAZIL CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. BRAZIL CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 92. BRAZIL CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 93. BRAZIL CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 94. BRAZIL CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 95. BRAZIL CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 96. BRAZIL CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 97. BRAZIL CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
  • TABLE 98. BRAZIL CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 99. BRAZIL CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 100. BRAZIL CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 101. BRAZIL CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. BRAZIL CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 103. BRAZIL CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. BRAZIL CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 105. CANADA CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. CANADA CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 107. CANADA CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 108. CANADA CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 109. CANADA CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 110. CANADA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 111. CANADA CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 112. CANADA CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
  • TABLE 113. CANADA CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 114. CANADA CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 115. CANADA CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 116. CANADA CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. CANADA CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 118. CANADA CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. CANADA CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 120. MEXICO CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. MEXICO CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 122. MEXICO CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 123. MEXICO CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 124. MEXICO CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 125. MEXICO CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 126. MEXICO CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 127. MEXICO CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
  • TABLE 128. MEXICO CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 129. MEXICO CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 130. MEXICO CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 131. MEXICO CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. MEXICO CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 133. MEXICO CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 134. MEXICO CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 135. UNITED STATES CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. UNITED STATES CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 137. UNITED STATES CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED STATES CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED STATES CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED STATES CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED STATES CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED STATES CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED STATES CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED STATES CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED STATES CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED STATES CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED STATES CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED STATES CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED STATES CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 150. UNITED STATES CELL & GENE THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 167. AUSTRALIA CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. AUSTRALIA CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 169. AUSTRALIA CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 170. AUSTRALIA CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 171. AUSTRALIA CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 172. AUSTRALIA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 173. AUSTRALIA CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 174. AUSTRALIA CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
  • TABLE 175. AUSTRALIA CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 176. AUSTRALIA CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 177. AUSTRALIA CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 178. AUSTRALIA CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 179. AUSTRALIA CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 180. AUSTRALIA CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 181. AUSTRALIA CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 182. CHINA CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. CHINA CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 184. CHINA CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 185. CHINA CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 186. CHINA CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 187. CHINA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 188. CHINA CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 189. CHINA CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
  • TABLE 190. CHINA CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 191. CHINA CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 192. CHINA CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 193. CHINA CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 194. CHINA CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 195. CHINA CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 196. CHINA CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 197. INDIA CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. INDIA CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 199. INDIA CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 200. INDIA CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 201. INDIA CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 202. INDIA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 203. INDIA CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 204. INDIA CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
  • TABLE 205. INDIA CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 206. INDIA CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 207. INDIA CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 208. INDIA CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 209. INDIA CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 210. INDIA CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 211. INDIA CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 212. INDONESIA CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. INDONESIA CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 214. INDONESIA CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 215. INDONESIA CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 216. INDONESIA CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 217. INDONESIA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 218. INDONESIA CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 219. INDONESIA CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
  • TABLE 220. INDONESIA CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 221. INDONESIA CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 222. INDONESIA CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 223. INDONESIA CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 224. INDONESIA CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 225. INDONESIA CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 226. INDONESIA CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 227. JAPAN CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. JAPAN CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 229. JAPAN CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 230. JAPAN CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 231. JAPAN CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 232. JAPAN CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 233. JAPAN CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 234. JAPAN CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
  • TABLE 235. JAPAN CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 236. JAPAN CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 237. JAPAN CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 238. JAPAN CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 239. JAPAN CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 240. JAPAN CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 241. JAPAN CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 242. MALAYSIA CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 243. MALAYSIA CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 244. MALAYSIA CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 245. MALAYSIA CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 246. MALAYSIA CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 247. MALAYSIA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 248. MALAYSIA CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 249. MALAYSIA CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
  • TABLE 250. MALAYSIA CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 251. MALAYSIA CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 252. MALAYSIA CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 253. MALAYSIA CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 254. MALAYSIA CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 255. MALAYSIA CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 256. MALAYSIA CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 257. PHILIPPINES CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 258. PHILIPPINES CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 259. PHILIPPINES CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 260. PHILIPPINES CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 261. PHILIPPINES CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 262. PHILIPPINES CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 263. PHILIPPINES CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 264. PHILIPPINES CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
  • TABLE 265. PHILIPPINES CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 266. PHILIPPINES CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 267. PHILIPPINES CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 268. PHILIPPINES CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 269. PHILIPPINES CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 270. PHILIPPINES CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 271. PHILIPPINES CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 272. SINGAPORE CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 273. SINGAPORE CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 274. SINGAPORE CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 275. SINGAPORE CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 276. SINGAPORE CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 277. SINGAPORE CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 278. SINGAPORE CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 279. SINGAPORE CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
  • TABLE 280. SINGAPORE CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 281. SINGAPORE CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 282. SINGAPORE CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 283. SINGAPORE CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 284. SINGAPORE CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 285. SINGAPORE CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 286. SINGAPORE CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 287. SOUTH KOREA CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 288. SOUTH KOREA CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 289. SOUTH KOREA CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 290. SOUTH KOREA CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 291. SOUTH KOREA CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 292. SOUTH KOREA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 293. SOUTH KOREA CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 294. SOUTH KOREA CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
  • TABLE 295. SOUTH KOREA CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 296. SOUTH KOREA CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 297. SOUTH KOREA CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 298. SOUTH KOREA CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 299. SOUTH KOREA CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 300. SOUTH KOREA CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 301. SOUTH KOREA CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 302. TAIWAN CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 303. TAIWAN CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 304. TAIWAN CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 305. TAIWAN CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 306. TAIWAN CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 307. TAIWAN CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 308. TAIWAN CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 309. TAIWAN CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
  • TABLE 310. TAIWAN CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 311. TAIWAN CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 312. TAIWAN CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 313. TAIWAN CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 314. TAIWAN CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 315. TAIWAN CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 316. TAIWAN CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 317. THAILAND CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 318. THAILAND CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 319. THAILAND CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 320. THAILAND CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 321. THAILAND CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 322. THAILAND CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 323. THAILAND CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 324. THAILAND CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
  • TABLE 325. THAILAND CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 326. THAILAND CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 327. THAILAND CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 328. THAILAND CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 329. THAILAND CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 330. THAILAND CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 331. THAILAND CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 332. VIETNAM CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 333. VIETNAM CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 334. VIETNAM CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 335. VIETNAM CELL & GENE THERAPY MARKET